Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.

When Dr. Scott Braunstein moved from his position as chairman of the board and interim CEO to become permanent CEO of Marinus Pharmaceuticals in August 2019, he had already concluded an overbroad focus was holding the company back.

Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.

See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.

Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.

Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.

Taking the CBO position at Affimed offered Denise Mueller a way to apply her skills in an international biotech startup environment, where she could help shape the company’s innovative approach to cancer immunotherapy.

Funding bio startups has never been easy, but no doubt it just got harder. We wanted to find at least one company to talk about how it is handling the damage and aftermath of recent bank closures and other cash crunches, and we actually found two.

Kinaset Therapeutics is moving fast in the respiratory space to advance a potential first-time therapy.

Orca Bio is creating a new cell therapy aimed at bringing rebirth to stem-cell transplantation.

“Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.

Kriya’s firm commitment to build or bring all key functions in house may be unusual for such a young enterprise, but it has been consistent from the beginning.

Sonoma Biotherapeutics is bioengineering T cells to create potential cures for autoimmune and inflammatory conditions.

KaliVir Immunotherapeutics is engineering oncolytic viruses with novel transgenes, and joining them to other immunotherapies, to defeat cancer and cancer relapse.